

## Special Issue

# 10th Anniversary of Biomedicines—Induced Pluripotent Stem Cells: 15 Years after the Discovery

### Message from the Guest Editor

It is our great pleasure to announce the 10th anniversary of the journal *Biomedicines*. To celebrate this anniversary, we are launching a Special Issue entitled “10th Anniversary of *Biomedicines*—Induced pluripotent stem cells: 15 years after the discovery”. Since the creation of induced pluripotent stem cells (iPSCs), by the Nobel Prize laureate Dr. Shinya Yamanaka, many laboratories worldwide are working to generate and apply these cells to the investigation of the ethiopathogeny behind diseases and the search for new therapies against them. The aim of this Special Issue is to collect high-quality papers, fully dedicated to iPSCs and their applications, from top experts in this field. In particular, we encourage researchers to present comprehensive review papers and original articles that highlight the most recent advances in this topic.

- induced pluripotent stem cells
- organoids
- tissue engineering
- biomaterials
- reprogramming
- iPSC-based cell modelling
- cell therapy
- microfluidics
- drug discovery

### Guest Editor

Dr. M. Esther Gallardo

Head of Translational Research with iPS Cells Group, Research Institute Hospital 12 de Octubre, i+12, Madrid, Spain

### Deadline for manuscript submissions

closed (30 November 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/107853](https://mdpi.com/si/107853)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).